From: A review of research-supported group treatments for drug use disorders
Study | Patient Characteristicsa | Treatment Description | Manual | Study Characteristicsb | Results |
---|---|---|---|---|---|
Jaffe et al., 2007 [70] | 145 methamphetamine-dependent (DSM-IV) gay and bisexual males. Mean age 37 years, 100% male, 80% White,12% Hispanic. | 1. CBT (control condition; 90-min group, 48 session available) 2. Contingency management (CM) (Participants did not need to attend CBT sessions they were only provided vouchers for attending clinic visits) 3. CBT + CM (90-min groups + opportunity to earn vouchers) 4. “Gay Specific” CBT (90-min group session occurred three times per week) | 1. Yes 2. No 3. Yes 4. Did not report | RAWC; No follow up reported. | Participants’ in the “Gay Specific” CBT condition reported the most rapid decline in levels of methamphetamine use relative to the other 3 treatment conditions. Participants’ in the control condition reported the highest rates of methamphetamine use. |
Rawson et al., 2004 [71] Rawson et al., 2002) [62]. | 978 treatment seeking individuals with methamphetamine abuse or dependence (DSM-IV checklist), without medical detoxification from opioids/alcohol/ other drugs. Mean age 33 years, 55% female, 18% Hispanic. | 1. Treatment as usual (TAU; contact with site 1–13 h. per week). 2. Matrix Model (MM; 16-weeks; 36 cognitive behavioral therapy groups, 12 family education groups, 4 social support groups, 4 individual counseling sessions, combined with weekly testing for cocaine, methamphetamine, opiates, cannabis and benzodiazepines. 12-Step meetings encouraged. | 1. No 2. Yes | RAWC; 6-month f/u, 81% f/u rate at post-tx, 86% f/u rate at 6-months. Mean tx contact in TAU was 12 sessions, mean tx contact for Matrix group was 27 sessions. | MM participants attended more sessions, stayed in treatment longer, provided more methamphetamine-free urine samples during the treatment and had longer periods of abstinence than TAU. Drug use and functioning at discharge and 6-month f/u indicate significant improvement by participants in all sites and conditions, but the superiority of MM approach did not persist at f/u. |
Roll et al., 2013 [72] | 118 participants with methamphetamine dependence (DSM-IV checklist) without a recent suicide attempt (past 30 days), suicidal ideation, parole status or history of violent criminal behavior, and medical condition that could interfere with treatment | 1. Standard psychosocial treatment (ST) based on the Matrix Model 2. ST + 1 month of CM 3. ST + 2 months of CM 4. ST + 4 months of CM | 1. Yes 2. Yes 3. Yes 4. Yes | RAWC; Retention rates were: 37% completed ST, 67% completed 1 month of CM, 53% completed 2 months of CM, 76% completed 4 months of CM. Post-treatment 4 month f/u; 42% for the ST condition, 43% for the 1 month of CM, 62% for the 2 month of CM, and 64% for the 4 month CM. | The standard treatment group was significantly different from the 4-month CM condition. The group conditions remained abstinent as follows: 3.4% of the ST condition, 13.3% of 1 month of CM condition, 20.0% of the 2-month condition, and 34.5% of the 4 month CM condition. Participants in the 4-month CM condition were more likely to attend f/u session and submit negative urine samples than participants in the ST condition. Results indicated that attendance, consecutive days of methamphetamine abstinence, and the number of participants who remained 100% or 80% abstinent throughout the trial increased as the duration of CM went up. |
Shoptaw et al., 2006 [73] | 229 treatment seeking individuals with methamphetamine abuse or dependence (SCID) and without medical condition, current treatment with a selective serotonin reuptake inhibitor, a psychiatric condition, or dependence on opioids, cocaine, alcohol, or benzodiazepines. Mean age 33 years, 38% female, 23% Latino. | 2-week non-medication baseline with 12 weeks of medication tx and: 1. Sertraline plus Contingency Management (S-CM; 4 weekly relapse prevention groups, three times per week) 2. Sertraline-only (S) 3. Placebo medication plus CM (P-CM) 4. Placebo medication (P) | 1.Yes 2. No 3. Yes 4. No | RAWC; post-treatment f/u; 50.7% completed all 14 weeks of the trial. | No effects for sertraline or CM in reducing methamphetamine use were observed. S had significantly poorer retention and produced significantly more adverse events than P-CM or P. More participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. |